Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.

Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW.

Nat Commun. 2018 Dec 17;9(1):5341. doi: 10.1038/s41467-018-07551-w.

2.

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.

McCoull W, Cheung T, Anderson E, Barton P, Burgess J, Byth K, Cao Q, Castaldi MP, Chen H, Chiarparin E, Carbajo RJ, Code E, Cowan S, Davey PR, Ferguson AD, Fillery S, Fuller NO, Gao N, Hargreaves D, Howard MR, Hu J, Kawatkar A, Kemmitt PD, Leo E, Molina DM, O'Connell N, Petteruti P, Rasmusson T, Raubo P, Rawlins PB, Ricchiuto P, Robb GR, Schenone M, Waring MJ, Zinda M, Fawell S, Wilson DM.

ACS Chem Biol. 2018 Nov 16;13(11):3131-3141. doi: 10.1021/acschembio.8b00698. Epub 2018 Oct 17.

PMID:
30335946
3.

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

Wang Z, Grosskurth SE, Cheung T, Petteruti P, Zhang J, Wang X, Wang W, Gharahdaghi F, Wu J, Su N, Howard RT, Mayo M, Widzowski D, Scott DA, Johannes JW, Lamb ML, Lawson D, Dry JR, Lyne PD, Tate EW, Zinda M, Mikule K, Fawell SE, Reimer C, Chen H.

Cancer Res. 2018 Dec 1;78(23):6691-6702. doi: 10.1158/0008-5472.CAN-18-1362. Epub 2018 Oct 8.

PMID:
30297535
4.

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.

Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB, Chen H.

PLoS One. 2018 Jul 23;13(7):e0200826. doi: 10.1371/journal.pone.0200826. eCollection 2018.

5.

BRD4 facilitates replication stress-induced DNA damage response.

Zhang J, Dulak AM, Hattersley MM, Willis BS, Nikkilä J, Wang A, Lau A, Reimer C, Zinda M, Fawell SE, Mills GB, Chen H.

Oncogene. 2018 Jul;37(28):3763-3777. doi: 10.1038/s41388-018-0194-3. Epub 2018 Apr 11.

6.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

7.

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum.

Greenawalt DM, Liang WS, Saif S, Johnson J, Todorov P, Dulak A, Enriquez D, Halperin R, Ahmed A, Saveliev V, Carpten J, Craig D, Barrett JC, Dougherty B, Zinda M, Fawell S, Dry JR, Byth K.

Oncotarget. 2017 Jun 15;8(59):99237-99244. doi: 10.18632/oncotarget.18502. eCollection 2017 Nov 21.

8.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.

Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H.

Mol Cancer Ther. 2016 Nov;15(11):2563-2574. Epub 2016 Aug 29.

9.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2016 Aug 23;7(34):54120-54136. doi: 10.18632/oncotarget.10852.

10.

Dissecting Therapeutic Resistance to ERK Inhibition.

Jha S, Morris EJ, Hruza A, Mansueto MS, Schroeder GK, Arbanas J, McMasters D, Restaino CR, Dayananth P, Black S, Elsen NL, Mannarino A, Cooper A, Fawell S, Zawel L, Jayaraman L, Samatar AA.

Mol Cancer Ther. 2016 Apr;15(4):548-59. doi: 10.1158/1535-7163.MCT-15-0172. Epub 2016 Feb 1.

11.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, Linsenmayer D, Hattersley M, Smith A, Wilson J, Cairo S, Déas O, Nicolle D, Adam A, Zinda M, Reimer C, Fawell SE, Clark EA, D'Cruz CM.

Clin Cancer Res. 2015 Jun 15;21(12):2811-9. doi: 10.1158/1078-0432.CCR-14-2685. Epub 2015 Mar 16.

12.

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.

Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2015 Feb 10;6(4):2407-20.

13.

MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.

Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P.

PLoS One. 2014 Oct 7;9(10):e108371. doi: 10.1371/journal.pone.0108371. eCollection 2014.

14.

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Fawell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S.

Cancer Discov. 2014 Oct;4(10):1154-67. doi: 10.1158/2159-8290.CD-13-0830. Epub 2014 Aug 7.

15.

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.

Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD.

Mol Cancer Ther. 2013 Aug;12(8):1442-52. doi: 10.1158/1535-7163.MCT-13-0025. Epub 2013 May 22.

16.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.

Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.

17.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK.

Transl Oncol. 2012 Dec;5(6):422-9. Epub 2012 Dec 1.

18.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.

Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, Cong F.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15473-8. doi: 10.1073/pnas.1007428107. Epub 2010 Aug 16.

19.

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.

Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, Yao YM, Kwon P, Fawell S, Atadja P.

Int J Cancer. 2010 Nov 1;127(9):2199-208. doi: 10.1002/ijc.25218.

20.

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.

Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F.

Nature. 2009 Oct 1;461(7264):614-20. doi: 10.1038/nature08356. Epub 2009 Sep 16.

PMID:
19759537
21.

Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.

Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R, Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM.

Cancer Res. 2008 Jan 15;68(2):561-70. doi: 10.1158/0008-5472.CAN-07-2307.

22.

A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.

Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, Sage D, Slisz J, Tran M, Straub C, Ramsey T, Iourgenko V, Huang A, Chen Y, Schlegel R, Labow M, Fawell S, Sellers WR, Zawel L.

Cancer Res. 2007 Dec 15;67(24):11493-8.

23.

The rag locus of Porphyromonas gingivalis contributes to virulence in a murine model of soft tissue destruction.

Shi X, Hanley SA, Faray-Kele MC, Fawell SC, Aduse-Opoku J, Whiley RA, Curtis MA, Hall LM.

Infect Immun. 2007 Apr;75(4):2071-4. Epub 2007 Feb 5.

24.

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL.

Cancer Res. 2006 Oct 1;66(19):9617-24.

25.

Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer.

Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC.

Cancer Res. 2005 Nov 15;65(22):10423-30.

26.

Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines.

Locke M, Heywood M, Fawell S, Mackenzie IC.

Cancer Res. 2005 Oct 1;65(19):8944-50.

27.

Sequence diversity and antigenic variation at the rag locus of Porphyromonas gingivalis.

Hall LM, Fawell SC, Shi X, Faray-Kele MC, Aduse-Opoku J, Whiley RA, Curtis MA.

Infect Immun. 2005 Jul;73(7):4253-62.

28.

Recognition of the carbohydrate modifications to the RgpA protease of Porphyromonas gingivalis by periodontal patient serum IgG.

Slaney JM, Rangarajan M, Aduse-Opoku J, Fawell S, Darby I, Kinane D, Curtis MA.

J Periodontal Res. 2002 Jun;37(3):215-22.

PMID:
12113557
29.

Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q, Liu W, Ellis L, Moscioni AD, Tazelaar J, Fawell S, Qin X, Propert KJ, Davis A, Fraker DL, Wilson JM, Spitz FR.

J Clin Invest. 2001 Jul;108(1):83-95.

30.

Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver.

Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE.

Mol Ther. 2001 Jan;3(1):28-35.

31.

Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14411-6.

32.

Fibronectin type III repeats mediate RGD-independent adhesion and signaling through activated beta1 integrins.

Chi-Rosso G, Gotwals PJ, Yang J, Ling L, Jiang K, Chao B, Baker DP, Burkly LC, Fawell SE, Koteliansky VE.

J Biol Chem. 1997 Dec 12;272(50):31447-52.

33.

Tat-mediated protein delivery can facilitate MHC class I presentation of antigens.

Moy P, Daikh Y, Pepinsky B, Thomas D, Fawell S, Barsoum J.

Mol Biotechnol. 1996 Oct;6(2):105-13.

PMID:
8970166
34.

The alpha1beta1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization.

Gotwals PJ, Chi-Rosso G, Lindner V, Yang J, Ling L, Fawell SE, Koteliansky VE.

J Clin Invest. 1996 Jun 1;97(11):2469-77.

35.

Generation of a potent chimeric toxin by replacement of domain III of Pseudomonas exotoxin with ricin A chain KDEL.

Pitcher C, Roberts L, Fawell S, Zdanovsky AG, FitzGerald DJ, Lord JM.

Bioconjug Chem. 1995 Sep-Oct;6(5):624-9.

PMID:
8974463
36.

Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin.

Chen LL, Frankel AD, Harder JL, Fawell S, Barsoum J, Pepinsky B.

Anal Biochem. 1995 May 1;227(1):168-75.

PMID:
7668378
37.

Tat-mediated delivery of heterologous macromolecules into living cells.

Barsoum J, Moore C, Seery J, Daikh Y, Chen LL, Corina K, Moy P, Brown R, Shapiro R, Taylor F, Androphy E, Pepinsky B, Fawell S.

Restor Neurol Neurosci. 1995 Jan 1;8(1):11-2. doi: 10.3233/RNN-1995-81203. No abstract available.

PMID:
21551797
38.

Tat-mediated delivery of heterologous proteins into cells.

Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J.

Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):664-8.

39.

Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen.

Danielian PS, White R, Hoare SA, Fawell SE, Parker MG.

Mol Endocrinol. 1993 Feb;7(2):232-40.

PMID:
8469236
40.

Effect of ligand binding and DNA binding on the structure of the mouse oestrogen receptor.

Emmas CE, Fawell SE, Hoare SA, Parker MG.

J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):291-9.

PMID:
1562507
41.

Role of ligand in oestrogen-receptor function.

Parker MG, Fawell SE, Danielian P, Arbuckle N.

Biochem Soc Trans. 1991 Nov;19(4):897-9. No abstract available.

PMID:
1794579
42.

Analysis of oestrogen receptor dimerisation using chimeric proteins.

White R, Fawell SE, Parker MG.

J Steroid Biochem Mol Biol. 1991;40(1-3):333-41.

PMID:
1720327
43.

Mechanism of estrogen receptor-dependent transcription in a cell-free system.

Elliston JF, Fawell SE, Klein-Hitpass L, Tsai SY, Tsai MJ, Parker MG, O'Malley BW.

Mol Cell Biol. 1990 Dec;10(12):6607-12.

44.
45.

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG.

Proc Natl Acad Sci U S A. 1990 Sep;87(17):6883-7.

46.
47.

Identification of two transactivation domains in the mouse oestrogen receptor.

Lees JA, Fawell SE, Parker MG.

Nucleic Acids Res. 1989 Jul 25;17(14):5477-88.

48.

A proposed consensus steroid-binding sequence--a reply.

Fawell SE, Lees JA, Parker MG.

Mol Endocrinol. 1989 Jun;3(6):1002-5.

PMID:
2739652
49.
50.

A specific insulin receptor and tyrosine kinase activity in the membranes of Neurospora crassa.

Fawell SE, Lenard J.

Biochem Biophys Res Commun. 1988 Aug 30;155(1):59-65.

PMID:
2970849

Supplemental Content

Loading ...
Support Center